TY - JOUR
T1 - Losigamone
T2 - A putative antiepileptic drug
AU - Morris, George L.
AU - Collins, Susan
AU - Bell, Walter
AU - Sahlroot, J. Todd
AU - Matula, Margaret
AU - Cereghino, James J.
N1 - Funding Information:
From the ‘Department of Neurology, Medical College of Wisconsin, Milwaukee, WI; ‘Epilepsy Branch, National Institutes of Neurological Disorders and Stroke, Bethesda, MD; 3Food and Drug Administration, Division of Biometrics, National Institute of Allergy and Infectious Diseases, *Division of AIDS, and 50regon Health SciencesU niversity, Portland, OR, U.S.A.
PY - 1997/3/4
Y1 - 1997/3/4
N2 - Losigamone (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39% was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.
AB - Losigamone (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39% was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.
KW - Antiepileptic drugs
KW - Controlled clinical trial
KW - Drug toxicity
KW - Losigamone
KW - Partial seizures
UR - http://www.scopus.com/inward/record.url?scp=0031552134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031552134&partnerID=8YFLogxK
U2 - 10.1016/S0896-6974(96)00085-0
DO - 10.1016/S0896-6974(96)00085-0
M3 - Article
AN - SCOPUS:0031552134
SN - 0896-6974
VL - 10
SP - 62
EP - 66
JO - Journal of Epilepsy
JF - Journal of Epilepsy
IS - 2
ER -